Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Pozycja w akcjach #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Cena akcji
$150.78
Ostatnia synchronizacja: 2026-09-18
Kapitalizacja rynkowa
$187.20B
Zmiana (1 dzień)
-0.08%
Zmiana (1 rok)
32.15%
Kraj
US
Handel Gilead Sciences, Inc. (GILD)

Kategoria

Marża operacyjna dla Gilead Sciences, Inc. (GILD)
Marża operacyjna na dzień September 2026 TTM: -4.90%
Według najnowszych raportów finansowych i ceny akcji Gilead Sciences, Inc., bieżąca marża operacyjna (TTM) wynosi -4.90%. Na koniec 2024 wynosiła 5.78%.
Historia marży operacyjnej dla Gilead Sciences, Inc. od 2000 do 2026
Marża operacyjna na koniec każdego roku
Rok Marża operacyjna Zmień
2026 (TTM) -4.90% -114.39%
2025 34.04% 488.93%
2024 5.78% -79.39%
2023 28.05% 4.39%
2022 26.87% -26.02%
2021 36.32% 120.25%
2020 16.49% -13.66%
2019 19.10% -48.46%
2018 37.06% -31.50%
2017 54.10% -6.76%
2016 58.02% -14.68%
2015 68.00% 10.88%
2014 61.33% 51.84%
2013 40.39% -2.27%
2012 41.33% -8.56%
2011 45.20% -9.31%
2010 49.84% -0.99%
2009 50.34% 0.28%
2008 50.20% -1.90%
2007 51.17% -304.11%
2006 -25.07% -145.85%
2005 54.68% 15.46%
2004 47.36% -359.08%
2003 -18.28% -205.36%
2002 17.35% -133.60%
2001 -51.63% 93.01%
2000 -26.75% 0.00%
Marża operacyjna dla podobnych firm lub konkurentów
Firma Marża operacyjna Różnica w marży operacyjnej Kraj
43.92% -108.96%
US
26.81% -105.47%
US
29.32% -105.98%
US
26.59% -105.43%
CH
16.65% -103.40%
US
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.